105 related articles for article (PubMed ID: 11200072)
1. CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens.
Jahrsdörfer B; Hartmann G; Racila E; Jackson W; Mühlenhoff L; Meinhardt G; Endres S; Link BK; Krieg AM; Weiner GJ
J Leukoc Biol; 2001 Jan; 69(1):81-8. PubMed ID: 11200072
[TBL] [Abstract][Full Text] [Related]
2. B-cell lymphomas differ in their responsiveness to CpG oligodeoxynucleotides.
Jahrsdorfer B; Mühlenhoff L; Blackwell SE; Wagner M; Poeck H; Hartmann E; Jox R; Giese T; Emmerich B; Endres S; Weiner GJ; Hartmann G
Clin Cancer Res; 2005 Feb; 11(4):1490-9. PubMed ID: 15746051
[TBL] [Abstract][Full Text] [Related]
3. CD40-dependent and -independent activation of human tonsil B cells by CpG oligodeoxynucleotides.
Gantner F; Hermann P; Nakashima K; Matsukawa S; Sakai K; Bacon KB
Eur J Immunol; 2003 Jun; 33(6):1576-85. PubMed ID: 12778475
[TBL] [Abstract][Full Text] [Related]
4. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN.
Jahrsdörfer B; Jox R; Mühlenhoff L; Tschoep K; Krug A; Rothenfusser S; Meinhardt G; Emmerich B; Endres S; Hartmann G
J Leukoc Biol; 2002 Jul; 72(1):83-92. PubMed ID: 12101266
[TBL] [Abstract][Full Text] [Related]
5. CpG oligodeoxynucleotide-induced immunity prevents growth of germinal center-derived B lymphoma cells.
Ponzio NM; Cutro S; Hu J; Marzouk A; Marshall JD
Int Immunopharmacol; 2006 Dec; 6(13-14):2057-68. PubMed ID: 17161362
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antigen-presenting ability of B lymphoma cells by immunostimulatory CpG-oligonucleotides and anti-CD40 antibody.
Chen W; Yu Y; Shao C; Zhang M; Wang W; Zhang L; Cao X
Immunol Lett; 2001 May; 77(1):17-23. PubMed ID: 11348665
[TBL] [Abstract][Full Text] [Related]
7. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
Decker T; Schneller F; Sparwasser T; Tretter T; Lipford GB; Wagner H; Peschel C
Blood; 2000 Feb; 95(3):999-1006. PubMed ID: 10648415
[TBL] [Abstract][Full Text] [Related]
8. Rational design of new CpG oligonucleotides that combine B cell activation with high IFN-alpha induction in plasmacytoid dendritic cells.
Hartmann G; Battiany J; Poeck H; Wagner M; Kerkmann M; Lubenow N; Rothenfusser S; Endres S
Eur J Immunol; 2003 Jun; 33(6):1633-41. PubMed ID: 12778481
[TBL] [Abstract][Full Text] [Related]
9. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
Rieger R; Kipps TJ
Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017
[TBL] [Abstract][Full Text] [Related]
10. IFN-alpha amplifies human naive B cell TLR-9-mediated activation and Ig production.
Giordani L; Sanchez M; Libri I; Quaranta MG; Mattioli B; Viora M
J Leukoc Biol; 2009 Aug; 86(2):261-71. PubMed ID: 19401392
[TBL] [Abstract][Full Text] [Related]
11. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities.
Vollmer J; Weeratna R; Payette P; Jurk M; Schetter C; Laucht M; Wader T; Tluk S; Liu M; Davis HL; Krieg AM
Eur J Immunol; 2004 Jan; 34(1):251-62. PubMed ID: 14971051
[TBL] [Abstract][Full Text] [Related]
12. Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells.
Jahrsdörfer B; Wooldridge JE; Blackwell SE; Taylor CM; Griffith TS; Link BK; Weiner GJ
J Leukoc Biol; 2005 Mar; 77(3):378-87. PubMed ID: 15582984
[TBL] [Abstract][Full Text] [Related]
13. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity.
Vollmer J; Weeratna RD; Jurk M; Davis HL; Schetter C; Wüllner M; Wader T; Liu M; Kritzler A; Krieg AM
J Leukoc Biol; 2004 Sep; 76(3):585-93. PubMed ID: 15218053
[TBL] [Abstract][Full Text] [Related]
14. CpG-C ISS-ODN activation of blood-derived B cells from healthy and chronic immunodeficiency virus-infected macaques.
Teleshova N; Kenney J; Williams V; Van Nest G; Marshall J; Lifson JD; Sivin I; Dufour J; Bohm R; Gettie A; Pope M
J Leukoc Biol; 2006 Feb; 79(2):257-67. PubMed ID: 16443827
[TBL] [Abstract][Full Text] [Related]
15. Porcine-specific CpG-oligodeoxynucleotide activates B-cells and increases the expression of MHC-II molecules on lymphocytes.
Van der Stede Y; Verdonck F; Verfaillie T; Goddeeris BM; Cox E
Vet Immunol Immunopathol; 2005 May; 105(1-2):115-24. PubMed ID: 15797481
[TBL] [Abstract][Full Text] [Related]
16. CpG oligodeoxynucleotide-based therapy of lymphoid malignancies.
Weiner GJ
Adv Drug Deliv Rev; 2009 Mar; 61(3):263-7. PubMed ID: 19168102
[TBL] [Abstract][Full Text] [Related]
17. CpG ODN enhances the efficacy of rituximab in non-Hodgkin lymphoma.
Buhé V; Guerrier T; Youinou P; Berthou C; Loisel S
Ann N Y Acad Sci; 2009 Sep; 1173():858-64. PubMed ID: 19758238
[TBL] [Abstract][Full Text] [Related]
18. Anti-HBV effects of CpG oligodeoxynucleotide-activated peripheral blood mononuclear cells from patients with chronic hepatitis B.
Li N; Fan XG; Chen ZH; Huang Y; Quan J; Liu ZB
APMIS; 2005 Oct; 113(10):647-54. PubMed ID: 16309422
[TBL] [Abstract][Full Text] [Related]
19. Higher-order CpG-DNA stimulation reveals distinct activation requirements for marginal zone and follicular B cells in lupus mice.
Brummel R; Roberts TL; Stacey KJ; Lenert P
Eur J Immunol; 2006 Jul; 36(7):1951-62. PubMed ID: 16791898
[TBL] [Abstract][Full Text] [Related]
20. CpG-oligodeoxynucleotide protects immune cells from gamma-irradiation-induced cell death.
Sohn WJ; Lee KW; Choi SY; Chung E; Lee Y; Kim TY; Lee SK; Choe YK; Lee JH; Kim DS; Kwon HJ
Mol Immunol; 2006 Mar; 43(8):1163-71. PubMed ID: 16122803
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
